Day 2 of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2023 will be dedicated entirely to urothelial carcinoma. The first session of the day will deal with addressing challenges to ensure health equity in bladder cancer. Christine Ibilibor, MD, MSc, University of Virginia, is scheduled to present her research on eliminating differences in outcomes by race and gender, and Elad Sharon, MD, MPH, National Cancer Institute, will address health equity by expanding trial eligibility criteria.
At 10:00 am, the keynote session of the Symposium will take place. Norman E Sharpless, MD, University of North Carolina School of Medicine, will present “Ending Cancer as We Know It: Predicting Future Cancer Progress,” followed by a moderated Q&A.
Immediately afterwards will be a general session on innovations and multidisciplinary care in early- and late-stage disease. Presentation topics include methods to studying BCG-unresponsive non-muscle-invasive disease, next-generation therapies, and optimizing survival outcomes, among others.
The final general session of the day will include a presentation on patient-reported outcomes in cisplatin-ineligible patients with locally advanced or metastatic disease treated with enfortumab vedotin alone or in combination with pembrolizumab, followed by a moderated panel discussion.
